TCGA-OR-A5JP-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.423
- MYC_TARGETS_V2+0.373
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- CHOLESTEROL_HOMEOSTASIS+0.368
- G2M_CHECKPOINT+0.349
- PANCREAS_BETA_CELLS+0.347
- MTORC1_SIGNALING+0.332
- E2F_TARGETS+0.278
- PI3K_AKT_MTOR_SIGNALING+0.275
- ANGIOGENESIS+0.274
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.269
- INTERFERON_GAMMA_RESPONSE-0.238
- HEME_METABOLISM-0.202
- ALLOGRAFT_REJECTION-0.180
- APICAL_SURFACE-0.080
- KRAS_SIGNALING_UP-0.079
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.050
- P53_PATHWAY-0.043
- PROTEIN_SECRETION-0.033
- WNT_BETA_CATENIN_SIGNALING-0.029
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943009 | — | — | 0.832 |
| 2 | TCGA-52-7810-01A-11R-2125-07 | — | cohortSQ1 | 0.820 |
| 3 | AUR-AFR3-TTP1-A-2-1-R-A743-41 | — | C | 0.817 |
| 4 | TCGA-E9-A1N6-01A-11R-A144-07 | — | C | 0.795 |
| 5 | SRR35579803 | — | E | 0.790 |
| 6 | MNG296 | — | — | 0.790 |
| 7 | TCGA-YC-A89H-01A-11R-A36F-07 | — | — | 0.785 |
| 8 | BS_81SP2HX4 | Med | Medulloblastoma | 0.785 |
| 9 | MDT-AP-1249 | Med | Medulloblastoma | 0.771 |
| 10 | TCGA-C8-A135-01A-11R-A115-07 | — | C | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.423 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.373 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.368 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.349 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.347 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.332 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.278 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.275 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.274 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.269 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.256 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.254 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.201 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.197 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.188 | Inavolisib | — uncovered |
| PEROXISOME | 0.178 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.162 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.142 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |